T
Toni K. Choueiri
Researcher at Harvard University
Publications - 1230
Citations - 84800
Toni K. Choueiri is an academic researcher from Harvard University. The author has contributed to research in topics: Renal cell carcinoma & Sunitinib. The author has an hindex of 107, co-authored 1071 publications receiving 59514 citations. Previous affiliations of Toni K. Choueiri include University of Ulsan & University of British Columbia.
Papers
More filters
Journal ArticleDOI
Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial
Toni K. Choueiri,David J. Figueroa,André P. Fay,Sabina Signoretti,Yuan Liu,Robert C. Gagnon,Keith C. Deen,Christopher L. Carpenter,Peter Benson,Thai H. Ho,Lini Pandite,Paul de Souza,Thomas Powles,Robert J. Motzer +13 more
TL;DR: Increased tumor cell PD-L1, or PD- L1 plus tumor CD8-positive T-cell counts, were associated with shorter survival in patients with metastatic RCC receiving VEGF-targeted agents, which may have implications for future design of randomized clinical trials in advanced RCC.
Journal ArticleDOI
ClearCode34: A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma
Samira A. Brooks,A. Rose Brannon,Joel S. Parker,Jennifer C. Fisher,Oishee Sen,Michael W. Kattan,A. Ari Hakimi,James J. Hsieh,Toni K. Choueiri,Pheroze Tamboli,Jodi K. Maranchie,Peter Hinds,C. Ryan Miller,Matthew E. Nielsen,W. Kimryn Rathmell +14 more
TL;DR: The ClearCode34-based model provides prognostic stratification that improves upon established algorithms to assess risk for recurrence and death for nonmetastatic ccRCC patients and built a subtype-inclusive model to analyze patient survival outcomes.
Journal ArticleDOI
Overall survival in renal-cell carcinoma with pazopanib versus sunitinib.
TL;DR: Survival results are now mature for a noninferiority trial comparing pazopanib with sunitinib in renal-cell carcinoma, and a difference that wasnot significant is now mature.
Journal ArticleDOI
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial
Toni K. Choueiri,James Larkin,Mototsugu Oya,Fiona C Thistlethwaite,Fiona C Thistlethwaite,Marcella Martignoni,Paul Nathan,Thomas Powles,David F. McDermott,Paul B. Robbins,David D. Chism,Daniel Cho,Michael B. Atkins,Michael S. Gordon,Sumati Gupta,Hirotsugu Uemura,Yoshihiko Tomita,Anna Compagnoni,Camilla Fowst,Alessandra di Pietro,Brian I. Rini +20 more
TL;DR: The safety profile of the combination avelumab plus axitinib in treatment-naive patients with advanced renal-cell carcinoma seemed to be manageable and consistent with that of each drug alone, and the preliminary data on antitumour activity are encouraging.
Journal ArticleDOI
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.
Toni K. Choueiri,Mayer Fishman,Bernard Escudier,David F. McDermott,Charles G. Drake,Harriet M. Kluger,Walter M. Stadler,Jose Luis Perez-Gracia,Douglas G. McNeel,Brendan D. Curti,Michael R. Harrison,Elizabeth R. Plimack,Leonard Joseph Appleman,Lawrence Fong,Laurence Albiges,Lewis J. Cohen,Tina C. Young,Scott D. Chasalow,Petra Ross-Macdonald,Shivani Srivastava,Maria Jure-Kunkel,John F. Kurland,Jason S. Simon,Mario Sznol +23 more
TL;DR: Immunomodulatory effects of PD-1 inhibition were demonstrated through multiple lines of evidence across nivolumab doses in a hypothesis-generating prospective mRCC trial of previously treated patients with metastatic renal cell carcinoma.